title: Clinical evaluation of gemcitabine in dogs with spontaneously occurring malignancies.
abstract: We conducted a clinical evaluation of gemcitabine in 19 dogs with spontaneously occurring malignancies. The principal objectives of this study were to characterize toxicity and seek preliminary evidence of antitumor activity of gemcitabine administered every 2 weeks (biweekly) as a 30-minute IV infusion. A total of 64 doses, ranging from 300 mg/m2 to 675 mg/m2, were administered during the initial 8-week evaluation period, and an additional 131 doses were administered during the extended evaluation period. The total cumulative dose for the 10 dogs receiving gemcitabine in the extended evaluation period ranged from 1,500 mg/m2 to 24,300 mg/m2. Clinical evidence of toxicity was minimal. Cumulative myelosuppression was not apparent. Unexplained retinal hemorrhages occurred in 1 dog. No complete or partial remissions were observed during the initial evaluation period; however, objective responses were observed in 2 dogs during the extended evaluation period. Gemcitabine is a promising new chemotherapeutic agent that can be used safely in dogs with cancer. Biweekly administration of doses of 675 mg/m2 IV results in minimal and acceptable toxicity.
authors.affiliation: Department of Veterinary Clinical Sciences and Veterinary Teaching Hospital, Columbus, OH, USA.
authors.forename: Carrie E
authors.initials: CE
authors.lastname: Kosarek
authors.forename: William C
authors.initials: WC
authors.lastname: Kisseberth
authors.forename: Stacey L
authors.initials: SL
authors.lastname: Gallant
authors.forename: C Guillermo
authors.initials: CG
authors.lastname: Couto
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004353:Drug Evaluation, Preclinical / Q000662:veterinary; D005260:Female; D007262:Infusions, Intravenous; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine